Exploiting Nanotechnology for the Development of MicroRNA-Based Cancer Therapeutics

Tyagi, Nidhi; Arora, Sumit; Deshmukh, Sachin Kumar; Singh, Seema; Marimuthu, Saravanakumar; Singh, Ajay P.

doi:10.1166/jbn.2016.2172

Cited by 57 publications

(36 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This miRNA-based therapeutic strategy can efficiently inhibit expression of multidrug resistance gene and anti-apoptotic gene in cerebral GSCs (Tyagi et al, 2016). …”

Section: Categories Of Nanoparticlesmentioning

confidence: 99%

Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy

et al. 2016

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM), grade IV astrocytoma, is the most fatal malignant primary brain tumor. GBM contains functional subsets of cells called glioblastoma stem-like cells (GSCs), which are radioresistant and chemoresistant and eventually lead to tumor recurrence. Recent studies showed that GSCs reside in particular tumor niches that are necessary to support their behavior. To successfully eradicate GBM growth and recurrence, new strategies selectively targeting GSCs and/or their microenvironmental niche should be designed. In this regard, here we focus on elucidating the molecular mechanisms that govern these GSC properties and on understanding the mechanism of the microenvironmental signals within the tumor mass. Moreover, to overcome the blood–brain barrier, which represents a critical limitation of GBM treatments, a new drug delivery system should be developed. Nanoparticles can be easily modified by different methods to facilitate delivery efficiency of chemotherapeutics, to enhance the accumulation within the tumors, and to promote the capacity for targeting the GSCs. Therefore, nanotechnology has become the most promising approach to GSC-targeting therapy. Additionally, we discussed the future of nanotechnology-based targeted therapy and point out the disadvantages that should be overcome.

show abstract

“…This miRNA-based therapeutic strategy can efficiently inhibit expression of multidrug resistance gene and anti-apoptotic gene in cerebral GSCs (Tyagi et al, 2016). …”

Section: Categories Of Nanoparticlesmentioning

confidence: 99%

Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The delivery of miR-34a induced apoptosis and cell death, reduced migration, proliferation of breast cancer cells via targeting CD44 and Notch-1-signaling pathways [125]. In a similar study, doxorubicin and miR-34a loaded chitosan nanoparticles were delivered into breast cancer cells to increase therapeutic effects of drug [115,126]. …”

Section: Mirnas and Nanoparticle Delivery Systemsmentioning

confidence: 95%

Nanoparticle Based Delivery of miRNAs to Overcome Drug Resistance in Breast Cancer

Yalçın¹,

Gündüz²

2016

J Nanomed Nanotechnol

View full text Add to dashboard Cite

Nanoparticle-based targeted drug delivery is a successful strategy to overcome the side effect of chemotherapy. Nanoparticles based drug delivery systems that have been designed to enhance delivery of therapeutics to tumors, are a novel approach. Nanoparticles have reactive surface that can be readily modified with biocompatible coatings and loaded with therapeutic agents (miRNA, siRNA, antibody, anti-cancer drug etc..). MicroRNAs (miRNAs or miRs) are short non-coding RNAs which posttranscriptionally regulate growth, differentiation, apoptosis, motility, and malignant transformation. In addition, some miRNAs have been classified as proto-oncogenes. The levels of changed miRNA expression play significant role in the initiation of many diseases, including cancer, especially tumor progression and metastasis. Further studies, miRNA conjugation to drug carrier systems is used to target to cancer cells. In this review, we focus on miRNA carrier nanoparticles, and summarize novel advances about their use in drug resistance breast cancer therapy.

show abstract

“…Tratamiento del cáncer usando la nanotecnología El cáncer es el resultado de la acumulación de múltiples alteraciones en genes que regulan el crecimiento celular, traen consigo daños a nivel morfológico y metabólico en las células que las presentan, ya que muchas de estas alteraciones son irreversibles, considerándose de gran importancia un diagnóstico oportuno que garantice una recuperación eficaz de este tipo de patologías (48,49) . Para noviembre de 2016, investigadores de la Universidad de Sichuan en China, lograron inyectar por primera vez en un paciente con cáncer de pulmón, linfocitos genéticamente modificados con el fin de generar una respuesta inmune eliminado las células tumorales empleando la tecnología CRISPR-Cas, creando una reestructuración del gen que codifica la proteína PD-1 (Programmed Death-1), receptor de superficie celular que cuya función es la regulación negativa del sistema inmunitario y la promoción de la auto-tolerancia empleando como mecanismo la supresión de la actividad inflamatoria de las células T. Aunque existe la inmunoterapia en la que se puede inactivar el gen PD-1, se espera que esta nueva tecnología sea una estrategia terapéutica con mayor eficiencia y estabilidad (50) .…”

Section: Interpretación De La Información Codificada En El Adn Bacterunclassified

Aplicación de la nanobiotecnología con el sistema CRISPR-cas

2017

View full text Add to dashboard Cite

ResumenIntroducción: La nanobiotecnología y la biología sintética son ciencias que impactan en la actualidad con el lanzamiento de aplicaciones innovadoras y beneficiosas para el ser humano, estas ciencias se han fusionado para fabricar nuevos componentes para la construcción de células totalmente artificiales y la creación de biomoléculas sintéticas. Objetivo: Conocer las aplicaciones de la nanobiotecnología relacionadas con el uso del sistema CRISPR/Cas en el almacenamiento de información en el ADN bacteriano y alternativas terapéuticas. Materiales y métodos: Se realizó una revisión bibliográfica sobre las principales aplicaciones de la nanobiotecnología, en las bases de datos ScienceDirect, SciELO, PubMed y en revistas como: Nature biotechnology, Biochemistry, Science y Journal Microbiology. Resultados: La revisión de literatura describe y analiza las nuevas aplicaciones nanobiotecnológicas utilizadas para escribir información en el código genético de las células bacterianas, en el que se emplean el sistema basado en repeticiones palindrómicas cortas agrupadas y regularmente interespaciadas (CRISPR/Cas) y la producción de ADN sintético, así como las alternativas terapéuticas relacionadas con la terapia génica. Conclusión: Entre las aplicaciones nanobiotecnológicas se han demostrado dos métodos para grabar información en el ADN de células bacterianas, de Escherichia coli y Sulfolobus tokodai vinculados con el empleo del sistema CRISPR/Cas y la producción de ADN sintético, así como el uso del CRISPR/Cas en la terapia génica y celular.Palabras clave: Biotecnología; ADN recombinante; proteínas asociadas a CRISPR; memoria inmunológica; ingeniería genética. (Fuente: DeCS, Bireme). AbstractIntroduction: Nanobiotechnology and synthetic biology are sciences that impact today with the launching of innovative and beneficial applications for the human being. These sciences have been amalgamated to manufacture new components for the construction of totally artificial cells and the creation of synthetic biomolecules. Objective: To know the applications of nanobiotechnology related to the use of the system CRISPR/Cas in the storage of bacterial DNA and therapeutic alternatives. Materials and methods: A bibliographical review on the main applications of nanobiotechnology was carried out in ScienceDirect, SciELO, PubMed databases and in magazines such as: Nature Biotechnology, Biochemistry, Science and Journal Microbiology. Results: The literature review describes and analyzes the new nanobiotechnology applications used to write information in the genetic code of bacterial cells, in which the system is used based on short grouped and regularly interspaced palindromic repetitions (CRISPR/Cas) and the production of synthetic DNA, as well as therapeutic alternatives related to gene therapy. Conclusion: Among the nanobiotechnology applications, two methods to record information in the DNA of bacterial

show abstract

Exploiting Nanotechnology for the Development of MicroRNA-Based Cancer Therapeutics

Cited by 57 publications

References 0 publications

Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy

Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy

Nanoparticle Based Delivery of miRNAs to Overcome Drug Resistance in Breast Cancer

Aplicación de la nanobiotecnología con el sistema CRISPR-cas

Contact Info

Product

Resources

About